NEXGEL, Inc.
NEXGEL, Inc. (NXGL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nxgl · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NEXGEL, Inc.You NXGL | $5M | N/A | — | — |
 Enlivex Therapeutics Ltd. ENLV | $18M | 0.03x | — | $27.04 |
 Femasys Inc. FEMY | $19M | N/A | — | -$9.42 |
 CytoMed Therapeutics Limited GDTC | $13M | N/A | — | -$0.34 |
 Harvard Bioscience, Inc. HBIO | $26M | N/A | — | -$12.77 |
 Inspira Technologies Oxy B.H.N. Ltd. IINN | $45M | N/A | — | -$0.45 |
 Milestone Scientific Inc. MLSS | $34M | N/A | — | -$0.07 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NEXGEL, Inc. (NXGL) measures how much investors pay for each dollar of the company's trailing earnings. NXGL's current PE ratio of N/A is calculated by dividing its stock price of $0.55 by its TTM earnings per share of —.
Frequently asked questions
NXGL pe ratio · 6 questionsNXGL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.55 and TTM EPS of —. Data sourced from Financial Modeling Prep via NXGL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NEXGEL, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09